The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Major Depressive Disorder (MDD) is an extremely disabling, chronic and recurrent disease. Moreover, subthreshold depressive symptoms often persist during periods of apparent remission. Such symptoms include sleep disturbances, sexual dysfunction, weight gain, fatigue, disinterest, anxiety, and/or emotional blunting, which do not often respond to available antidepressant treatments. Agomelatine is a melatonergic agonist (at both MT1 and MT2 receptors) and serotonin 2C (5-HT2C) receptor antagonist. Agomelatine should be particularly useful in the treatment of MDD because of its unique pharmacological profile, accounting for its effective antidepressant action with a relative lack of serious adverse effects. Several clinical trials confirmed the antidepressant efficacy of agomelatine in patients with MDD, with significant efficacy even in severe manifestations of disease and on residual subtreshold symptoms. This compound showed a relative early onset of action as well as an excellent safety and tolerability profile linked to a low discontinuation rate in MDD patients. Moreover, some data suggest that agomelatine has not only antidepressant effects but also anxiolytic effects, with a potential benefit both on anxiety symptoms associated with MDD and in the treatment of generalised anxiety disorder. This review will summarise the role of the melatonergic system in MDD and will describe the characteristics of agomelatine, focusing on its efficacy and safety in the treatment of MDD. Keywords: Agomelatine, circadian rhythms, efficacy, melatonin, major depressive disorder, tolerability, treatment, NCS-R, STAR D, Circadian Timing System, SCN, N-acetyl-5-methoxytryptamine, Zeitgeber, SPZ, norepinephrine, MDD, DMV, adrenocorticotropin, fluoxetine, duloxetine, hypericum perforatum, low melatonin syndrome, 5-HT2C, 5-HT1A, selective serotonin, SSRI, slow wave sleep, NREM, HAM-D, CYP1A, CYP2C9, CYP2C19, lorazepam, fluconazole, paroxetine, mirtazapine, sleep-phase syndrome, imipramine, Montgomery-Åsberg Depression Rating Scale, CGI, REM, electroconvulsive therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“The clinical manifestations of this disorder include affective, cognitive, somatic and behaviour symptoms [4, 5].”
BackgroundBelmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Action Spectrum for Melatonin Regulation in Humans: Evidence for a Novel Circadian Photoreceptor
Brainard, G. C., Hanifin, J. P., Greeson, J. M., Byrne, B., Glickman, G., Gerner, E., & Rollag, M. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-06405.2001 · Cited by 1,930 · cited 1×
“Circadian pacemaker regulation is also determined by neurotransmitter function and by the phase-shifting effects of various chemical or pharmacological components, including melatonin (N-acetyl-5-methoxytryptamine) [23].”
BackgroundA Phase Response Curve to Single Bright Light Pulses in Human Subjects
Khalsa, S. B. S., Jewett, M. E., Cajochen, C., & Czeisler, C. A. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.040477 · Cited by 1,040 · cited 2×
“[20].”
BackgroundMelatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 2×
“Furthermore, melatonin is considered to be the ‘hormone of darkness’ and the body’s chronological pacemaker or ‘Zeitgeber’ [24].”
BackgroundArendt, J., & Skene, D. J. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2004.05.002 · Cited by 629 · cited 1×
“Exogenous melatonin administration affects the phase of the circadian oscillator that regulates sleep/wakefulness [79, 80].”
BackgroundTreatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583
CIRCADIAN RHYTHMS: Basic Neurobiology and Clinical Applications
Moore MD, R. Y. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.253 · Cited by 400
Antidepressants and Sleep: A Qualitative Review of the Literature
Wilson, S., & Argyropoulos, S. (2005) · Drugs · doi:10.2165/00003495-200565070-00003 · Cited by 392 · cited 1×
“, fluoxetine increases nocturnal awakening later in treatment [123]), agomelatine does not produce insomnia, fragmentation of slowwave sleep, or nightmares.”
Background
Cited by
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Melatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d6c25 · Cited by 276
Self-citationRole of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Metadata
- Authors
- De Berardis, D., Di Iorio, G., Acciavatti, T., Conti, C., Serroni, N., Olivieri, L., Cavuto, M., Martinotti, G., Janiri, L., Saverio Moschetta, F., Conti, P., & Di Giannantonio, M.
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-02-01
- Volume
- 10
- Issue
- 1
- Pages
- 119-132
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W2158816287
- Cited by
- 76
- References
- 16
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine. https://app.cochat.ai/papers/10.2174/187152711794488674
- The paper
- De Berardis, D., Di Iorio, G., Acciavatti, T., Conti, C., Serroni, N., Olivieri, L., Cavuto, M., Martinotti, G., Janiri, L., Saverio Moschetta, F., Conti, P., & Di Giannantonio, M. (2011). The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/187152711794488674
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.